相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of perioperative chemotherapy in colorectal cancer metastatic to the liver
Lynn K. Symonds et al.
GASTROENTEROLOGY REPORT (2019)
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
Dominik P. Modest et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Theo Ruers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Theo Ruers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer A Systematic Review and Pooled Analysis
Gianluca Tomasello et al.
JAMA ONCOLOGY (2017)
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
T. Gruenberger et al.
ANNALS OF ONCOLOGY (2015)
Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer
Robert P. Jones et al.
EUROPEAN JOURNAL OF CANCER (2014)
Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983
E. Tanis et al.
EUROPEAN JOURNAL OF CANCER (2014)
Management of colorectal cancer presenting with synchronous liver metastases
Ajith K. Siriwardena et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria-A 10-Year Update
Muneeb Ahmed et al.
RADIOLOGY (2014)
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L. Fornaro et al.
ANNALS OF ONCOLOGY (2013)
A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial
Marc Ychou et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis
Jun Ho Ji et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases
Le-Chi Ye et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009
R. Adam et al.
ANNALS OF ONCOLOGY (2010)
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
Gianluca Masi et al.
LANCET ONCOLOGY (2010)
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
Gunnar Folprecht et al.
LANCET ONCOLOGY (2010)
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
Kyle E. Rusthoven et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX):: a phase II study in colorectal cancer patients with non-resectable liver metastases
M. Ychou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Neoadjuvant treatment of unresectable colorectal liver metastases:: correlation between tumour response and resection rates
G Folprecht et al.
ANNALS OF ONCOLOGY (2005)
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases
TM Pawlik et al.
ANNALS OF SURGERY (2005)
分享论文
